Mepolizumab subcutaneous (SC) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.6 [0.19, 1.85]3 studies · 1231 participantsHigh